MIDAZOLAM - Generic Drug Details

What are the generic drug sources for midazolam and what is the scope of freedom to operate?

Midazolam is the generic ingredient in nine branded drugs marketed by B Braun Medical, Exela Pharma, Gland, Hikma, Inforlife, Ucb Inc, Apothecon, Baxter Hlthcare Corp, Bedford, Ben Venue, Epic Pharma Llc, Fresenius Kabi Usa, Gland Pharma Ltd, Hospira, Hospira Inc, Igi Labs Inc, Intl Medicated, Intl Medication, Micro Labs, Ph Health, Rising, Onesource Specialty, HLR, Rafa Labs Ltd, MMT, Padagis Us, Pai Holdings, Pharm Assoc, Sun Pharm Inds Ltd, and Roche, and is included in forty-six NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are nine drug master file entries for midazolam. Seven suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for MIDAZOLAM

US Patents:	5
Tradenames:	9
Applicants:	30
NDAs:	46
Drug Master File Entries:	9
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	48
Clinical Trials:	1,722
Drug Prices:	Drug price trends for MIDAZOLAM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MIDAZOLAM
What excipients (inactive ingredients) are in MIDAZOLAM?	MIDAZOLAM excipients list
DailyMed Link:	MIDAZOLAM at DailyMed

See drug prices for MIDAZOLAM

Recent Clinical Trials for MIDAZOLAM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Novartis Pharmaceuticals	PHASE1
Canadian Institutes of Health Research (CIHR)	PHASE3
Unity Health Toronto	PHASE3

See all MIDAZOLAM clinical trials

Generic filers with tentative approvals for MIDAZOLAM

Applicant	Application No.	Strength	Dosage Form
		EQ 5MG BASE/ML	INJECTABLE;INJECTION
		5MG	SPRAY;NASAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for MIDAZOLAM

Drug Class

Benzodiazepine

Anatomical Therapeutic Chemical (ATC) Classes for MIDAZOLAM

N05CD	Benzodiazepine derivatives
N05C	HYPNOTICS AND SEDATIVES
N05	PSYCHOLEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for MIDAZOLAM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NAYZILAM	Nasal Spray	midazolam	5 mg/spray	211321	1	2021-06-01

US Patents and Regulatory Information for MIDAZOLAM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE	midazolam hydrochloride	INJECTABLE;INJECTION	075857-002	Jul 22, 2002	AP	RX	No	Yes
Hikma	MIDAZOLAM IN 0.9% SODIUM CHLORIDE	midazolam	SOLUTION;INTRAVENOUS	216159-001	Apr 17, 2023	AP	RX	No	No
Hlr	VERSED	midazolam hydrochloride	INJECTABLE;INJECTION	018654-002	May 26, 1987		DISCN	Yes	No
Hospira Inc	MIDAZOLAM HYDROCHLORIDE	midazolam hydrochloride	INJECTABLE;INJECTION	075409-001	Jun 20, 2000		DISCN	No	No
Rising	MIDAZOLAM HYDROCHLORIDE	midazolam hydrochloride	INJECTABLE;INJECTION	075494-002	Jun 30, 2000	AP	RX	No	No

EU/EMA Drug Approvals for MIDAZOLAM

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Neuraxpharm Pharmaceuticals S.L.	Buccolam	midazolam	EMEA/H/C/002267Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from three months to less than 18 years).Buccolam must only be used by parents / carers where the patient has been diagnosed to have epilepsy.For infants between three and six months of age, treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.	Authorised	no	no	no	2011-09-04

Market Dynamics and Financial Trajectory for Midazolam

Last updated: January 15, 2026

Summary

Midazolam, a potent benzodiazepine sedative, plays a vital role in anesthesia, sedation, and treatment of acute seizures. Its market landscape is shaped by factors such as regulatory environments, clinical applications, patent statuses, and emerging alternatives. This analysis explores the current market dynamics, financial movements, and future trajectory of Midazolam, providing a comprehensive view for investors, pharmaceutical companies, and healthcare policymakers.

---

What Are the Key Market Drivers for Midazolam?

Clinical Demand and Therapeutic Use

Midazolam’s primary functions include:

• Preoperative sedation
• Procedural sedation
• Anesthesia induction
• Status epilepticus management

The increasing global incidence of surgeries and neurological emergencies fuels demand. The World Health Organization reports over 300 million surgical procedures annually, with anesthesia agents like Midazolam playing a crucial role [1].

Regulatory Approvals and Labeling

Regulators such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved Midazolam for various indications. Its inclusion in emergency kits for seizure control and anesthesia protocols ensures sustained demand.

Market Expansion and Adoption

Emerging markets in Asia-Pacific demonstrate rising adoption, driven by expanding healthcare infrastructure, increasing urbanization, and growing awareness of sedation protocols. For example, China and India reported compounded annual growth rates (CAGRs) of 5-7% in sedation medication markets between 2018-2022 [2].

---

What Are the Challenges and Constraints in the Midazolam Market?

Patent Status and Generic Competition

Many formulations of Midazolam have lost patent exclusivity around 2010-2015, leading to widespread generic availability, which intensifies price competition and constrains revenue potential for branded products.

Safety and Regulatory Concerns

Potential adverse effects, including respiratory depression and paradoxical reactions, necessitate strict administration protocols. Regulatory agencies periodically reassess safety data, which can affect market stability.

Emerging Alternatives and Technology Shifts

• Newer sedatives like dexmedetomidine offer benefits such as reduced respiratory depression.
• Non-benzodiazepine agents and advanced sedation devices are gaining traction, possibly reducing Midazolam's market share.

---

How Has the Financial Trajectory Evolved Historically?

Market Size and Revenue Trends

Globally, the Midazolam market was valued at approximately $200 million in 2018 and experienced a compound annual growth rate (CAGR) of 3.5-4% up to 2022 [3]. The growth is primarily driven by:

Year	Estimated Market Size	Key Factors
2018	$200 million	Increasing surgical procedures, generic market penetration
2019	$208 million	Expanded indications, rising awareness
2020	$217 million	COVID-19 pandemic temporarily disrupting elective surgeries
2021	$226 million	Recovery in elective procedures
2022	$235 million	Market maturation and expanding emerging markets

Revenue Breakdown by Region

Region	Market Share (2022)	Growth Rate	Key Drivers
North America	~45%	3-4% annual	Established healthcare infrastructure
Europe	~25%	2-3%	Aging population, procedural volume growth
Asia-Pacific	~20%	5-7%	Healthcare expansion, population growth
Rest of World	~10%	2-3%	Limited access, regulatory variability

Major Players and Market Concentration

Brand production is dominated by a handful of pharmaceutical firms, with key players including:

Company	Estimated Market Share	Notable Products	Notes
Hospira (Pfizer)	~45%	Generic Midazolam	Major supplier for hospitals
Fresenius Kabi	~20%	Versed	Strong presence in Europe
Others	35%	Multiple generics	Increasing competition

---

What Are Projections for the Future?

Market Growth Outlook (2023-2030)

Analysts project the Midazolam market will grow at a CAGR of 3-5% over the next decade, reaching approximately $330-$375 million by 2030 [4].

Projection Variables	Impact Factors
Healthcare infrastructure	Continued expansion in emerging markets
Regulatory environment	Stringent safety regulations may limit certain formulations
Technological advances	Development of novel sedation agents could reduce reliance on Midazolam
Patent status	Impact of patent expirations on pricing and competition

Key Revenue Opportunities

• New formulation development: Longer-acting or ultra-fast formulations
• Combination therapies: Midazolam as part of multi-agent protocols
• Emerging markets: Rapid infrastructure growth opening new adoption avenues

Potential Risks

• Competitive pressure from generic and alternative agents
• Regulatory restrictions on safety profiles
• Global crises (e.g., pandemics) disrupting supply chains and elective procedures

---

Comparison with Other Sedative Agents

Agent	Class	Indications	Advantages	Limitations	Estimated Market Share (2022)
Midazolam	Benzodiazepine	Sedation, anesthesia, seizures	Rapid onset, short duration	Respiratory depression, paradoxical reactions	80% (sedative market)
Diazepam	Benzodiazepine	Sedation, muscle relaxation	Long half-life	Extended sedation, accumulation	10%
Dexmedetomidine	Alpha-2 adrenergic agonist	Sedation, intubation	Less respiratory depression	Hemodynamic effects	5%
Others	Various	Adjuncts	Specific to protocols	Varying efficacy	5%

---

FAQs

1. How does patent expiration affect Midazolam's market?

Patent expiration around 2010-2015 led to a flood of generic versions, intensifying price competition, decreasing revenue margins for branded producers, and transforming market dynamics into a highly commoditized landscape.

2. What emerging trends could influence Midazolam’s future demand?

Advances in sedation technology, development of alternative agents like dexmedetomidine, and personalized medicine approaches could curtail reliance on Midazolam. Simultaneously, expanding healthcare access in emerging markets will sustain demand.

3. How critical are regulatory considerations for Midazolam's market?

Regulatory bodies' safety assessments influence formulation approvals, labeling, and indications. Safety concerns, especially respiratory risks, lead to stringent guidelines that can affect prescribing practices and market size.

4. What are the primary therapeutic indications expanding for Midazolam?

Beyond traditional uses in anesthesia and procedural sedation, Midazolam is increasingly used in emergency management of status epilepticus, especially in hospital settings.

5. What competitive strategies are companies adopting in this segment?

Key strategies include developing improved formulations (long-acting or fast-acting), competitive pricing due to generic proliferation, and regional market expansion, primarily targeting Asia-Pacific.

---

Key Takeaways

• Market landscape is characterized by mature generic segments, with revenues driven by increased global surgical and emergency care needs.
• Growth prospects remain moderate (~3-5% CAGR), with future expansion fueled by emerging markets and technological innovation.
• Competitive pressures from generics and new sedative agents pose challenges, compelling innovation in formulation and delivery.
• Regulatory scrutiny around safety profiles remains pivotal; ongoing assessments influence market access.
• To capitalize on future opportunities, companies should focus on formulation innovation, regional expansion, and strategic alliances.

---

References

[1] WHO Surgical Procedures Data, 2021.
[2] Industry Reports on Asian Sedatives Market, 2022.
[3] MarketWatch, "Global Midazolam Market Analysis 2018-2022," 2022.
[4] Future Market Insights, "Sedatives Market Forecast 2023-2030," 2023.